Taysha Q2 Loss Widens to $46.6M, Cash Runway Extended to 2H 2028
TSHA has more than doubled off its 52-week low of $2.685.
Summary
Taysha Gene Therapies reported a Q2 net loss of $46.64 million, up from the prior year, driven by higher R&D and manufacturing costs for its lead gene therapy TSHA-102. Operating expenses hit $47.35 million with no revenue. The company completed a $230 million follow-on offering, extending its cash runway into the second half of 2028, past potential BLA approval. Topline data from the pivotal REVEAL trial and FDA feedback are now expected in the first half of 2027. The widening loss and increased spending underscore the heavy investment ahead of a potential commercial launch, but the extended runway reduces near-term financing risk.
At the time of this announcement, TSHA was trading at $6.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.69 to $7.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.